Cibinetide
Cibinetide, a peptide. An 11-residue peptide modelled on the helix-B region of erythropoietin, which is the face of the hormone that does NOT contact the…
An 11-residue peptide modelled on the helix-B region of erythropoietin, which is the face of the hormone that does NOT contact the erythropoietic receptor. It therefore activates only the innate repair receptor — a heterodimer of the EPO receptor and the beta common receptor, expressed not in healthy tissue but induced by injury and inflammation — while leaving the EPOR homodimer alone. That split is the whole point of the molecule: recombinant EPO cannot be used for tissue protection because it raises haematocrit and activates platelets, and this peptide separates the protective signal from the erythropoietic one. Studied for sarcoidosis-associated small-fibre neuropathy, diabetic neuropathy and diabetic macular oedema.
PubChem CID 91810664 (C51H84N16O21); sequence pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser. A 54-record title screen of everything PubMed indexes under the INN found no PK-dedicated paper, and the six human trials (PMID:23168581 sarcoidosis, PMID:28475703 dose-ranging, PMID:25387363 type 2 diabetic neuropathy, PMID:32674280 diabetic macular oedema, PMID:26431906, PMID:24136731) report efficacy, safety and pharmacodynamics only. THE "~2 min" HALF-LIFE IS DELIBERATELY NOT STORED and the reasoning is worth keeping, because thymosin-alpha-1 in this catalog DID take a half-life from a narrative review and carries a provenance caveat for it: that precedent predates the 2026-09-08 standard ("accuracy, and if accuracy is not possible dont do it") and should not be extended. Three reviews repeat the figure (PMID:25728128, PMID:27634443 as "HBSP", PMID:38943972 with no number at all) and the primary measurement behind it is not in PubMed. Worth noting the pharmacology makes the number nearly irrelevant to a curve anyway: the molecule's entire premise, stated in its own review's title, is that a short-lived peptide flips a switch whose effects far outlast plasma, so a two-minute Bateman curve would model the wrong quantity even if it were sourced. DOSES are from the trials: IV 2 mg three times weekly (PMID:23168581, 12 active / 10 placebo), SC 1, 4 or 8 mg daily for 28 days in 64 subjects (PMID:28475703), SC 4 mg daily (PMID:25387363, PMID:32674280). Mechanism references PMID:25728128 (innate repair receptor, verbatim) and PMID:38488446, a mouse knockdown showing the neuroprotective effect is "significantly suppressed following the injection of siRNA against betaCR".
Sources: PMID:25728128, PMID:38488446, PMID:23168581, PMID:28475703, PMID:25387363, PMID:32674280